An interventional study of Automated Lateral Rotation Therapy in Respiratory Insufficiency, Pressure Injury and Intensive Care Medicine, sponsored by University of Sao Paulo General Hospital. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-22.
Sponsored by University of Sao Paulo General Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Respiratory Insufficiency by University of Sao Paulo General Hospital — 5 open to participants now, 6 under way, none of them phase 3. Respiratory Insufficiency · University of Sao Paulo General Hospital.
Among the 13 studies in Respiratory Insufficiency by University of Sao Paulo General Hospital, this one is one of 3 that started in 2024, is one of 8 with no phase, and was the 13th registered.
1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.
Browse Respiratory Insufficiency studies →5 of the 13 studies in Respiratory Insufficiency by University of Sao Paulo General Hospital are open now, in 1 country. Recruiting first, the newest first:
University of Sao Paulo General Hospital · Sites in Brazil
Ages 18+
University of Sao Paulo General Hospital · Sites in Brazil
Ages 18+
University of Sao Paulo General Hospital · Sites in Brazil
Ages 18+
University of Sao Paulo General Hospital · Sites in Brazil
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 60 across 861 interventional studies indexed under Respiratory Insufficiency.
Median enrollment 40 across the 9 interventional studies, 202 across the 4 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Sao Paulo General Hospital is the lead sponsor of 612 studies on the registry; 99 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
1 of the studies in Respiratory Insufficiency by University of Sao Paulo General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06819943University of Sao Paulo General HospitalEffectiveness of Platform-Based Lateralization Therapy in Reducing Interface Pressure Between The Patient And The Support Surface | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Respiratory Insufficiency by University of Sao Paulo General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pressure injury (PI) is characterized as damage to the skin and/or underlying tissues resulting from sustained pressure or a combination of pressure and shear forces between the patient and the support surface. Prolonged pressure is a well-established risk factor in the development of PIs. Frequent repositioning and routine patient care have been recognized for decades as integral components of PI prevention and treatment protocols.
The duration of interface pressure is as critical as its magnitude. When interface pressure exceeds the mean capillary blood pressure, blood flow can be compromised, leading to ischemia in affected areas, which may progress to necrosis if sustained over time. Furthermore, it is widely accepted in the literature that tissue becomes at risk when interface pressure exceeds 30 to 32 mmHg.
In this context, continuous lateral rotation therapy (CLRT) offers a potential alternative for managing critically ill patients. CLRT involves continuous mechanical rotation of the patient in the lateral plane. However, its effects on skin integrity remain poorly understood. Despite the rationale behind and widespread recommendation of repositioning, the lack of robust evaluations on how repositioning impacts interface pressure creates uncertainty, underscoring the need for high-quality trials to assess different strategies for implementation.
Although lateralization is a pragmatic strategy for preventing pressure injuries, its use in critically ill patients requires an integrated assessment of respiratory, hemodynamic, and gastroesophageal effects. Therefore, this study proposes an innovative approach by evaluating, for the first time, the effectiveness of automated postural change with simultaneous monitoring of tissue integrity, pulmonary function, cardiovascular stability, and gastroesophageal protection. The aim is to optimize pressure injury prevention, improve pulmonary mechanics, ensure hemodynamic stability, and preserve gastroesophageal safety in critically ill patients.
The objective of this study is to evaluate the effectiveness of Automated Lateral Rotation Therapy in reducing interface pressure between the patient and the support surface, considering different head-of-bed elevations, in mechanically ventilated patients. This is a multidimensional approach, assessing the effects on respiratory, hemodynamic, and gastroesophageal parameters.
This is a single-center, intra-individual crossover randomized clinical trial, using a Latin square allocation model, conducted in an intensive care unit.
The study will compare the effects of automated platform lateralization at 15 degrees and 30 degrees, combined with a 10-degree head-of-bed elevation, to the supine position with a 30-degree head-of-bed elevation, focusing on the reduction of interface pressure. Lateral tilting will be performed to both sides (right and left) according to prior randomization. Each position will be maintained for 10 minutes, followed by a 10-minute washout period in the supine position before transitioning to the next condition.
Additionally, after completing the crossover assessments, a subgroup of six patients will undergo an extended monitoring phase. In this step, the lateralized position at 30 degrees with a 30-degree head-of-bed elevation will be maintained for two continuous hours on each side (right and left) to assess the temporal evolution of interface pressure, determining whether pressure values remain stable or tend to increase over time.
The intervention will be conducted using the Linet Multicare bed, equipped with the Symbioso mattress, which features Continuous Low Pressure (CLP) and Microclimate Management (MCM) modes. This system enables manual or automated lateral tilting of the entire bed platform up to 30 degrees on the axial axis. The CLP mode provides automatic, continuous low-pressure redistribution, minimizing interface pressures regardless of weight distribution or patient movement. The MCM mode includes a vapor-impermeable cover that reduces skin moisture and heat, supporting skin integrity and preventing maceration.
Monitoring Procedures Interface pressure monitoring will be performed using the ForeSite Intelligent Surface (Xsensor, Canada), a sensor network embedded in a mattress cover composed of 6136 sensing cells distributed over an area of 762 by 1880 millimeters, with a spatial resolution of 31.75 millimeters. The system provides continuous pressure acquisition at 3 Hz, operating in the range of 5 to 200 mmHg (0.7 to 36.6 kPa), with an accuracy of plus or minus 2 mmHg. During the protocol, interface pressure will be monitored continuously with real-time visual feedback displayed on a bedside LCD monitor, allowing visualization of pressure redistribution throughout the interventions.
Pulmonary monitoring will be conducted using the ENLIGHT (Timpel, model 2100, Brazil), which utilizes a 32-electrode belt placed around the thorax at the mid-axillary line to provide real-time monitoring of ventilation distribution through electrical impedance tomography (EIT).
Hemodynamic monitoring will be performed using the FloTrac system coupled with the EV1000 platform (Edwards Lifesciences, Irvine, California, USA), connected to a peripheral arterial catheter, enabling continuous measurement of cardiac output, cardiac index, stroke volume, stroke volume variation, and blood pressure parameters.
Gastroesophageal pH monitoring will be carried out using the AL-4 pH monitoring system (ALACER, Brazil), which includes an antimony pH probe with an external reference electrode placed on the patient's thoracic skin to continuously measure esophageal pH levels.
Primary Hypothesis Automated Lateral Rotation Therapy promotes a reduction in interface pressure, assessed by peak pressure, mean pressure, and the absolute count of sensors recording pressure above 40 mmHg. Additionally, it is hypothesized that the extent of this reduction varies depending on the degree of lateral tilt and head-of-bed elevation, with lower degrees potentially being more effective for pressure redistribution.
Secondary Hypotheses Automated lateral positioning improves respiratory mechanics, contributing to better ventilation and oxygenation.
Adverse hemodynamic effects are minimized when using controlled tilt angles. Automated lateral rotation does not increase the incidence of gastroesophageal reflux.
Primary Outcome Reduction in peak pressure in the sacral region.
Secondary Outcomes Peak pressure mean pressure in the occipital, scapular, and calcaneal regions. Mean pressure in the sacral, occipital, scapular, and calcaneal regions. Number of sensors with pressure above 32, 40, and 60 mmHg in the sacral, occipital, scapular, and calcaneal regions.
Respiratory parameters including static compliance, driving pressure, oxygenation, and volumetric capnography.
Hemodynamic parameters including heart rate, blood pressure, cardiac output, cardiac index, stroke volume, and stroke volume variation.
Gastric pH variation during different positioning conditions. Adverse events including hypotension, accidental ventilator disconnection, respiratory discomfort, or significant gastroesophageal reflux.
Pre-intervention Procedures
Before starting the protocol, a standardized preparation process will be performed to ensure clinical stability, measurement accuracy, and consistency across all participants. The following procedures will be applied:
Closed-system suctioning to minimize secretion accumulation and avoid measurement artifacts.
Adjustment of ventilator settings in Volume-Controlled Ventilation (VCV) mode, using a square wave flow pattern. Respiratory rate (RR), inspiratory-to-expiratory ratio (I:E), fraction of inspired oxygen (FiO₂), and tidal volume (Vt) will be maintained according to baseline parameters.
Positive End-Expiratory Pressure (PEEP) will be maintained at the baseline value plus 2 cmH₂O during lateralization phases, to compensate for potential changes in thoracic mechanics and prevent derecruitment.
Placement of the interface pressure sensor (ForeSite PT, XSENSOR) will be performed by two trained professionals to ensure correct positioning, alignment, and reduction of artifacts.
Bed surface and sensor positioning will be inspected to eliminate any folds, misalignments, or sensor displacements that could interfere with pressure measurements.
The esophageal pH monitoring system will be zeroed and calibrated before each change in the head-of-bed elevation, ensuring accurate pH recording.
Proton pump inhibitor (PPI) administration will be rescheduled prior to the protocol, and the enteral feeding tube must be confirmed in a post-pyloric position, reducing the risk of reflux and interference with pH measurements.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental positioning protocol with automated lateral rotation. After allocation, each participant is assigned to an initial lateralization side (right or left) and an initial head-of-bed elevation (10 or 30 degrees). The protocol begins with arterial blood gas sampling in the supine position. Lateralization follows a fixed sequence of 15 and 30 degrees, held for 10 minutes each, first on the assigned side and then on the opposite side. Each position is separated by a 10-minute washout period in the supine position with the same head-of-bed elevation. After completing this sequence, the participant returns to the supine position, and the second head-of-bed elevation (the one not initially assigned) is applied, repeating the same sequence starting again from the same lateralization side assigned initially. At the end of the protocol, a post-protocol arterial blood gas is collected. All positions are maintained for 10 minutes each.
Procedure: Automated Lateral Rotation Therapy
Platform-based automated lateral tilt system integrated into the Linet Multicare bed, which allows the entire bed platform to be tilted laterally up to 30 degrees along the axial axis, either manually or automatically. The system includes Continuous Low Pressure (CLP) mode, which automatically redistributes pressure to maintain low interface pressure, and Microclimate Management (MCM) to control moisture and heat at the skin interface. The intervention is designed to redistribute interface pressure as a preventive strategy against pressure injuries in critically ill patients.
Interface Pressure
The interface pressure will be measured from the pressure reading made by the XSensor. The average pressure, peak pressure, and median pressure will be used for each region of the body. In addition to the absolute count of pressure sensors that made a reading above 32, 40 and 60mmHg.
Time frame: Pressure measurements correspond to the mean value during the 10 minutes of each position, for both head-of-bed inclinations. In the extended monitoring phase, data are collected continuously for 2 hours on each side.
Driving Pressure
Driving Pressure (cmH2O) will be measured using the information provided by the EIT that uses the movement equation
Time frame: Readings will be taken immediately before changing to the next position, after stabilization in each position, during the protocol.
End Expiratory Lung Volume
Will be measured using the information provided by the Electrical Tomography Impedance
Time frame: Readings will be taken immediately before changing to the next position, after stabilization in each position, during the protocol.
Ventilatory Distribution
Will be measured using the information provided by the Electrical Tomography Impedance
Time frame: Readings will be taken immediately before changing to the next position, after stabilization in each position, during the protocol.
Plateau Pressure
Plateau Pressure( cmH2O) will be measured using the information provided by the EIT that uses the movement equation.
Time frame: Readings will be taken immediately before changing to the next position, after stabilization in each position, during the protocol.
Esophageal reflux
Measurement with pH meter probe from Alacer Biomédica.
Time frame: It uses a pH probe that will be kept continuously during the protocol. The pH curve over time is analyzed offline using the software provided by ALACER.
Diastolic Blood Pressure
The hemodynamics were assessed through Diastolic Blood Pressure using the multiparameter monitor DX-2020 (Dixtal, São Paulo, Brazil).
Time frame: Readings will be taken immediately before changing to the next position, after stabilization in each position, during the protocol.
Mean Arterial Pressure
The hemodynamics were assessed through Mean Artial Pressure using the multiparameter monitor DX-2020 (Dixtal, São Paulo, Brazil).
Time frame: Readings will be taken immediately before changing to the next position, after stabilization in each position, during the protocol.
Systolic Blood Pressure
The hemodynamics were assessed through Systolic Blood Pressure using the multiparameter monitor DX-2020 (Dixtal, São Paulo, Brazil).
Time frame: Readings will be taken immediately before changing to the next position, after stabilization in each position, during the protocol.
Heart Rate
The hemodynamics were assessed through Heart Rate using the multiparameter monitor DX-2020 (Dixtal, São Paulo, Brazil).
Time frame: Readings will be taken immediately before changing to the next position, after stabilization in each position, during the protocol.
Plan to share: No
Started Jun 2024 (actual). Primary completion is estimated for Dec 2026, 30 months after the start.
Of 360 non-industry interventional studies with no phase under Respiratory Insufficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 30 months is above that.
Counting every sponsor, half of 376 studies reached it within 24 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Sao Paulo General Hospital →